A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This European, prospective, multicentre, double-blind randomised study will evaluate the effect of lanreotide (120 mg every 28 days until disease progression) versus placebo in patients with metastatic/locally advanced, non-resectable, duodeno-pancreatic neuroendocrine tumours.
Epistemonikos ID: 5494504a47168cc6ae0b560c36806092ea391b35
First added on: May 12, 2024